Europe Solidaire Sans Frontières
Gilead Sciences announces deal to manufacture generic versions of lenacapavir, but critics say it excludes many countries where incidence is highest
Cheaper versions of the “gamechanger” HIV prevention drug lenacapavir are to be made available in 120 low- and middle-income countries, (…)
On Aug. 14, 2024, the World Health Organization declared mpox a public health emergency of international concern. There have been over 15,600 cases and over 530 deaths reported in the Democratic Republic of the Congo and neighboring countries in Africa. The disease had previously caused a global (…)
The global health system needs to wake up to the reality that an outbreak in one part of the world is a concern for everyone.
The mpox outbreak in Africa is yet another example of how infectious diseases perceived to be “someone else’s problem”, and affecting mainly poor, developing countries, (…)
More than four years from the onset of the pandemic, a fuller and more nuanced picture of long COVID is emerging. As the puzzle pieces fall into place, researchers are gaining a clearer understanding of how even mild cases of COVID-19 can translate into long-lasting and debilitating health (…)
AstraZeneca withdrawing it COVID vaccine from the market has nothing to do with blood clots.
The Oxford-AstraZeneca vaccine was a critical part of the COVID-19 pandemic response. However, on May 7 2024, the European Commission announced the vaccine is no longer authorised for use.
This EU (…)
Research shows that even mild COVID-19 can lead to the equivalent of seven years of brain aging. Victor Habbick Visions/Science Photo Library via Getty Images
From the very early days of the pandemic, brain fog emerged as a significant health condition that many experience after COVID-19. (…)
Several new studies reveal that getting multiple COVID vaccine doses provides strong protection against lingering symptoms
Doctor prepping a woman’s arm with alcohol swab prior to administering vaccination injection Credit: Jacob Lund/Alamy Stock Photo
At least 200 million people worldwide (…)
Researchers still don’t know how well BA.2.86 will evade immunity or whether it will cause more severe disease than its predecessors.
The latest variant, or sublineage, of SARS-CoV-2 to emerge on the scene, BA.2.86, has public health experts on alert as COVID-19 hospitalizations begin to rise (…)
Over the last fifty years, few public health professionals have considered Marxism relevant, and few Marxists have treated pandemics as an imminent concern. We offer this paper to help both public health professionals and socialists view pandemics through a Marxist lens. Although our theory is (…)
Getting scientists to develop a medicine is a relatively small part of the solution to a pandemic. The more difficult thing is to get the medicine to the people who need it
If you were a South African health journalist during the late 1990s and early 2000s, you were mostly an Aids reporter. (…)
Governments worldwide are abandoning people to a debilitating disease with one simple trick: saying it no longer exists.
In this article written for Truthout, Tithi Bhattacharya raises, from personal experience, questions about the present and future impact of the Covid pandemic and current (…)
There are a range of reasons people with long COVID may have poorer mental health.
Many people have persistent symptoms after recovering from COVID, a condition termed “long COVID”. The UK’s Office for National Statistics estimates 1.8 million people in the UK have long COVID symptoms at least (…)
A recent study found 59% of people with long COVID had damage to at least one organ a year after their initial symptoms.
The latest data from the Office for National Statistics suggests that more than 1.2 million people in the UK report living with long COVID for 12 months or more.
Several (…)
As rich people plough money into ventilation to protect themselves, those with long Covid are treated as an embarrassment.
You could see Covid-19 as an empathy test. Who was prepared to suffer disruption and inconvenience for the sake of others, and who was not? The answer was often (…)
The new bivalent boosters against COVID-19 have failed to halt omicron infections. However, new technologies are being developed that pave a way forward.
By almost any measure, the vaccination campaign against SARS-CoV-2, the virus that causes COVID-19, has been a global success.
As of (…)
Nearly all the wastewater samples from aircraft arriving in the UK showed evidence of COVID-infected passengers on board.
Small traces of many pathogens, such as viruses we may be infected with, are excreted when we go to the toilet. Ultimately, these agents find their way to municipal (…)
The debate over the risks of reinfections – which are likely to continue – could determine what precautions people take, but experts disagree on the data.
A recent study states that Covid-19 reinfections could pose additional risks to people’s long-term health – as compared to only getting (…)
After a year of omicron variants, will we ever see a new variant of concern?
The omicron variant of SARS-CoV-2, the virus that causes COVID-19, has now been around for more than a year. Before omicron became dominant, there had been a quick succession of named variants of concern – from alpha, (…)
While there are still far more questions than answers about long COVID-19, researchers are beginning to get a clearer picture of the health and economic consequences of the condition.
The Research Brief is a short take about interesting academic work.
The big idea
Even mild COVID-19 cases (…)
Masks are an easy and low-cost way to reduce the amount of virus entering the air and spreading to others.
The cold and flu season of 2022 has begun with a vengeance. Viruses that have been unusually scarce over the past three years are reappearing at remarkably high levels, sparking a (…)
Twitter
Facebook